GSK_Annual_Report_2021

Notes to the Standalone Financial Statements for the year ended March 31, 2021 (contd.) Financial Statements GlaxoSmithKline Pharmaceuticals Limited 140 Note 50 : Segment Reporting An operating segment is one whose operating results are regularly reviewed by the entity’s chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance. The Company has identified the Chief Operating Decision Maker as its Managing Director. The Chief Operating Decision Maker reviews performance of pharmaceutical business on an overall basis. As the Company has a single reportable segment, the segment wise disclosure requirements of Ind AS 108 on Operating Segment is not applicable. In compliance to the said standard, Entity-Wide disclosures are as under : ( ` in lakhs) Year ended March 31, 2021 Year ended March 31, 2020 Revenues from external customers attributed to the country of domicile and attributed to all foreign countries from which the company derives revenues Revenue from the Country of Domicile- India 3179,10.33 3207,22.07 Revenue from foreign countries 14,63.30 17,45.95 Total 3193,73.63 3224,68.02 ( ` in lakhs) As at March 31, 2021 As at March 31, 2020 Details of non current asset Non Current asset from the Country of Domicile- India 786,22.63 1229,05.15 Non Current asset from foreign countries - - Total 786,22.63 1229,05.15 Information about major customers The Company did not have any external revenue from a particular customer which exceeded 10% of total revenue. Note 51 : Related Party Disclosures Related party disclosures, as required by IND AS 24, “Related Party Disclosures”, notified under Section 133 of the Companies Act, 2013 are given below: 1 Relationships (during the year): (i) Shareholders (the GlaxoSmithKline (GSK) Group shareholding) in the Company: Glaxo Group Limited, U.K. GlaxoSmithKline Pte Limited, Singapore Eskaylab Limited, U.K. Burroughs Wellcome International Limited, U.K. Holding company / ultimate holding company of the above shareholders GlaxoSmithKline Plc, U.K. * GlaxoSmithKline Finance Plc, U.K.* Setfirst Ltd, U.K. * SmithKline Beecham Limited, U.K. Wellcome Limited, U.K.* The Wellcome Foundation Limited, U.K.*